# A Safety Study of NNZ-2566 in Patients With Rett Syndrome

> **NCT01703533** · PHASE2 · COMPLETED · sponsor: **Neuren Pharmaceuticals Limited** · enrollment: 67 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** NNZ-2566
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01703533
- **Lead sponsor:** Neuren Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2018-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703533, "A Safety Study of NNZ-2566 in Patients With Rett Syndrome". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01703533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*